Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
愛文思控股於2024年11月7日發佈新聞稿稱，該全球生物製藥公司致力於爲面臨嚴重疾病的患者提供首創和最佳療法，今天宣佈向27名新員工授予誘導獎勵。根據納斯達克規則5635(c)(4)，這些獎勵經過了愛文思控股的薪酬委員會批准，並作爲每位新員工加入公司的主要誘因。
In connection with the commencement of their employment, the employees received options on November 1, 2024 to purchase an aggregate 66,740 shares of Insmed common stock at an exercise price of $68.32 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
爲配合他們的就職，員工們於2024年11月1日獲得了期權，以購買愛文思控股普通股66,740股，行使價格爲每股68.32美元，該價格是授予當日納斯達克全球精選市場收盤交易價格。
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
該期權爲期10年，有四年的解鎖計劃，其中約25%的股票在相關授予日期的第一週年解鎖，並且每隔六個月其餘的12.5%的股票將解鎖，直到相關授予日期的第四年週年，取決於相關員工在適用的解鎖日期之前是否繼續在Insmed工作。
About Insmed
關於Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
insmed公司是一家以人爲本的全球生物製藥公司，致力於提供一流和最佳療法，改變患有嚴重疾病的患者的生活。該公司正在推進一系列已獲批和中後期研究的藥物以及聚焦於爲需求最大的患者群體提供服務的尖端藥物發現。insmed最先進的項目涉及肺部和炎症疾病，包括在美國、歐洲和日本獲批用於治療慢性、令人衰弱的肺部疾病的一種治療方法。該公司的早期研究項目涵蓋各種技術和模式，包括基因療法、AI驅動的蛋白工程、蛋白質製造、RNA端連接和合成拯救。
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit to learn more.
總部位於新澤西州布里奇沃特，insmed在美國、歐洲和日本各地設有辦公室和研究場所。insmed自豪地成爲生物製藥行業最佳僱主之一，包括連續四年獲得科學頂級僱主第一的榮譽。訪問，以了解更多。
Contact:
聯繫方式：
Investors:
投資者:
Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
[email protected]
Bryan Dunn
執行董事，投資者關係
(646) 812-4030
請輸入您的電子郵件地址。
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
[email protected]
Michael V. Morabito博士
投資者關係董事
(917) 936-8430
[email protected]
Gianna De Palma
Manager, Investor Relations
(873) 886-2236
[email protected]
Gianna De Palma
投資者關係經理
(873) 886-2236
[email protected]
Media:
媒體:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
[email protected]
Mandy Fahey
企業通信副總裁
(732) 718-3621
[email protected]
SOURCE Insmed Incorporated
Insmed Incorporated
